艾伯维获机构关注，计划投资3.8亿美元扩建产能

Core Viewpoint - AbbVie has gained attention from multiple institutions, reflecting a positive outlook on its long-term prospects with new investments and personnel appointments [2][3]. Institutional Perspectives - RBC Capital initiated coverage of AbbVie on February 25, 2026, with an "Outperform" rating and a target price of $260 [2]. - Barclays Bank also initiated coverage on February 20, 2026, with a "Buy" rating and a target price of $275, indicating strong institutional confidence in the company's future [2]. Recent Events - AbbVie announced plans to invest $380 million in building two new active pharmaceutical ingredient production facilities in Illinois to expand its neuroscience and weight-loss drug capacity, with more investment plans expected to be announced this year [3]. - The company appointed Jag Dosanjh as Senior Vice President and President of Immunology on February 21, 2026, to strengthen its management team [3]. - AbbVie will go ex-dividend on April 15, 2026, with a dividend payout of $1.73 per share [3]. Stock Performance - Over the past 7 days (February 20 to 27, 2026), AbbVie's stock price fluctuated by 0.99%, with a range of 5.09% [4]. - As of February 27, 2026, the stock price was $226.56, up 0.83% for the day, with a 5-day change of 0.78% [4]. - Year-to-date, the stock has slightly decreased by 0.05%, but it has increased by 11.16% over the past 52 weeks [4].